Understanding early signs of psychosis
ProNET: Psychosis-Risk Outcomes Network
This project collects brain scans, tests, and phone data from people at high risk for psychosis to find patterns that predict who may develop a psychotic disorder.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11382681 on NIH RePORTER |
What this research studies
You would join a network of sites that will follow about 1,040 people judged to be at clinical high risk for psychosis and 260 healthy volunteers over two years with eight visits. At visits they collect MRI and EEG brain measures, cognitive and symptom testing, genetic and body-fluid samples, natural speech recordings, and passive smartphone sensor and survey data. Biomarkers are measured at two timepoints to track brain–behavior changes over time and link these measures to clinical outcomes. The work is done across 26 international sites and aims to identify subgroups and markers that could guide future prevention or treatment.
Who could benefit from this research
Good fit: Ideal candidates are people identified as being at clinical high risk for psychosis who can attend repeated visits and complete scans, EEG, blood draws, cognitive tests, and smartphone monitoring.
Not a fit: People without signs of being at high risk, those with an established psychotic disorder, or anyone unable or unwilling to undergo MRI/EEG, blood draws, or smartphone monitoring may not benefit from this project.
Why it matters
Potential benefit: If successful, this could help spot who is most likely to develop psychosis earlier and support more personalized prevention or treatment plans.
How similar studies have performed: Smaller single-site and multisite studies have suggested MRI, EEG, speech, and digital markers can help predict psychosis risk, but this large, multimodal network is a novel effort to improve prediction.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Woods, Scott W — Yale University
- Study coordinator: Woods, Scott W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.